Our mission is to improve healthspan by advancing arterial health as a foundation of longevity.
Advancing arterial health from research to real-world use for over 30 years.
Building on over 50 years of pioneering research by our founder, Dr. Michael O'Rourke, our revolutionary SphygmoCor vascular biosensing technology redefined the measurement of arterial health. By leveraging advanced sensors, it delivers unmatched insights into cardiovascular well-being, setting a new standard in vascular care.
1994ATCOR Medical is Born
Company founded by Dr. Michael O'Rourke in Sydney, Australia1996SphygmoCor® Mx Approval in Australia
First generation SphygmoCor® system receives TGA approval2000SphygmoCor® Mx Gains CE Mark
First generation SphygmoCor® system receives CE Mark2002SphygmoCor® Mx Approval in US
FDA clearance granted for first generation SphygmoCor® system2004US Division Established
AtCor Medical, Inc. formed in the US.2005IPO on ASX
AtCor Medical IPOs on ASX - ASX:ACG2007SphygmoCor® CvMS Approved in US
FDA clearance granted for second generation SphygmoCor® system2008SphygmoCor® CvMS Gains CE Mark
Second generation SphygmoCor® system receives CE Mark2012SphygmoCor® XCEL Approved in US
FDA clearance granted for third generation SphygmoCor® system2014SphygmoCor® XCEL Approved in China
China Food & Drug Administration (CFDA) approval granted for third generation SphygmoCor® system2015CPT Code Approval in US
AMA and CMS approved introduction of CPT code 93050 for arterial pressure waveform analysis2016Oscar 2 with Sphy Approved in US
Oscar 2 with SphygmoCor® Inside receives FDA clearance2018New Corporate Identity: CARDIEX
ATCOR Medical changes name to CARDIEX to reflect a strategic shift toward a broader, global health technology focus..2019CARDIEX China Established
CARDIEX establishes local operations in China with presence in Shanghai and Beijing2019Oscar 2 Approved in China
Oscar 2 with SphygmoCor® Inside receives China FDA approval2021CONNEQT Health Launched
CARDIEX launches CONNEQT Health to make advanced arterial health technology accessible to consumers.2022Ticwatch GTH Pro Smartwatch Launched
CARDIEX and Mobvoi Enter the US and Australia Markets with Revolutionary Consumer Heart Heath Monitoring Smartwatch2023CONNEQT Pulse Approved in US
FDA clearance granted for fifth generation SphygmoCor® system2024CONNEQT Pulse Added to FDA Validated Device Listing
CONNEQT Pulse included on the FDA Validated Device Listing, recognizing compliance with applicable regulatory and quality standards.2024CARDIEX Receives NIH RADx® Tech Maternal Health Award
CARDIEX recognized by the National Institutes of Health for advancing technology to support postpartum maternal health monitoring.2025CARDIEX Becomes CONNEQT Health
CARDIEX adopts the CONNEQT Health name to align its consumer and professional arterial health platforms.
"There is no greater health mission than prioritizing arterial wellness — because a world with healthy arteries is a world with boundless potential for life and vitality."
